Teriflunomide (Aubagio®) for the treatment of multiple sclerosis

被引：37
作者：
Bar-Or, Amit [1 ,2 ,3 ]
机构：
[1] McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada
[2] McGill Univ, Montreal Neurol Inst, Expt Therapeut Program, Montreal, PQ H3A 2B4, Canada
[3] McGill Univ, Montreal Neurol Inst, Clin Res Unit, Montreal, PQ H3A 2B4, Canada
来源：
EXPERIMENTAL NEUROLOGY | 2014年 / 262卷
关键词：
Multiple sclerosis; Immune modulation; Treatment; Aubagio; Teriflunomide; Leflunomide; AGOUTI RAT MODEL; DE-NOVO SYNTHESIS; PHASE-III TRIAL; ORAL TERIFLUNOMIDE; IMMUNOMODULATORY DRUG; RHEUMATOID-ARTHRITIS; T-LYMPHOCYTES; LEFLUNOMIDE; SAFETY; CELLS;
D O I：
10.1016/j.expneurol.2014.06.005
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Teriflunomide (Aubagio) is a once-daily oral immunomodulatory disease modifying therapy (DMT) presently approved in several regions, including Europe, North America, Latin America and Australia, for the treatment of relapsing forms of multiple sclerosis (RMS; RRMS). The therapeutic mode of action of teriflunomide in MS continues to be investigated. This review summarizes the main efficacy and safety results of the clinical trial program leading to teriflunomide's approval, highlights a number of practical clinical considerations, and overviews its presumed therapeutic mode of action (MOA) based on pharmacokinetic and pharmacodynamic observations and the growing body of teriflunomide-related in vitro, pre-clinical (animal model), and in vivo human studies. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码：57 / 65
页数：9
相关论文
共 52 条
[11]  
European Agency for the Evaluation of Medicinal Products, 1997, COMM PROPR MED PROD
[12]  
FAIRBANKS LD, 1995, J BIOL CHEM, V270, P29682
[13]   Teriflunomide added to interferon-β in relapsing multiple sclerosis A randomized phase II trial [J].
Freedman, M. S. ;
Wolinsky, J. S. ;
Wamil, B. ;
Confavreux, C. ;
Comi, G. ;
Kappos, L. ;
Olsson, T. P. ;
Miller, A. ;
Benzerdjeb, H. ;
Li, H. ;
Simonson, C. ;
O'Connor, P. W. .
NEUROLOGY, 2012, 78 (23) :1877-1885
[14]  
Freedman M.S., 2011, INT J MS CARE S3, V13, P17
[15]   Teriflunomide in relapsing multiple sclerosis: therapeutic utility [J].
Freedman, Mark S. .
THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2013, 4 (05) :192-205
[16]  
Freedman MS, 2014, 8 WORLD C CONTR NEUR
[17]   An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors [J].
Fuentealba, Rodrigo A. ;
Marasa, Jayne ;
Diamond, Marc I. ;
Piwnica-Worms, David ;
Weihl, Conrad C. .
HUMAN MOLECULAR GENETICS, 2012, 21 (03) :664-680
[18]   Teriflunomide: A Review of Its Use in Relapsing Multiple Sclerosis [J].
Garnock-Jones, Karly P. .
CNS DRUGS, 2013, 27 (12) :1103-1123
[19]   Pathophysiology of multiple sclerosis and the place of teriflunomide [J].
Gold, R. ;
Wolinsky, J. S. .
ACTA NEUROLOGICA SCANDINAVICA, 2011, 124 (02) :75-84
[20]   Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases [J].
Herrmann, ML ;
Schleyerbach, R ;
Kirschbaum, BJ .
IMMUNOPHARMACOLOGY, 2000, 47 (2-3) :273-289
123456